Quoin director awarded 12,211 ADS stock options

Quoin Pharmaceuticals reported that director Natalie Leong received a grant of share options for 12,211 American Depositary Shares (ADSs) on February 4, 2026.

Rhea-AI Filing Summary

Quoin Pharmaceuticals reported that director Natalie Leong received a grant of share options for 12,211 American Depositary Shares (ADSs) on February 4, 2026. The options have an exercise price of $7.37 per ADS and expire on February 4, 2036. Each ADS represents 35 ordinary shares of the company.

The option vests over four years, with 20% vesting on each of February 4, 2027, 2028, and 2029, and the remaining 40% vesting on February 4, 2030. Following this grant, Leong holds 12,211 derivative securities directly.

Insider Trade Summary

Grant/Award: 12,211 shares

Grant/Award 1 txn

Insider Leong Natalie Ee Mun

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	12,211	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 12,211 contracts (Direct)

Footnotes (2)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quoin Pharmaceuticals (QNRX) disclose for director Natalie Leong?

Quoin Pharmaceuticals disclosed a stock option grant to director Natalie Leong for 12,211 ADSs on February 4, 2026. These derivative securities are held directly and give her the right to buy ADSs at a fixed exercise price over a defined vesting schedule.

How many Quoin Pharmaceuticals (QNRX) ADS options were granted and at what exercise price?

Natalie Leong received options covering 12,211 American Depositary Shares at an exercise price of $7.37 per ADS. The grant is recorded as a derivative security with no purchase price paid for the option itself at the time of grant.

What is the vesting schedule for the Quoin Pharmaceuticals (QNRX) options granted to Natalie Leong?

The option vests in four annual installments: 20% on each of February 4, 2027, 2028, and 2029, and 40% on February 4, 2030. This staggered vesting structure aligns ongoing service as a director with the gradual earning of option rights.

When do the Quoin Pharmaceuticals (QNRX) director stock options expire?

The stock options granted to director Natalie Leong expire on February 4, 2036. She has the right, once vested, to exercise these options at $7.37 per ADS any time before this expiration date, subject to applicable plan rules and conditions.

How many derivative securities does Natalie Leong hold in Quoin Pharmaceuticals (QNRX) after this transaction?

After the reported transaction, Natalie Leong beneficially owns 12,211 derivative securities in the form of stock options. These options are held directly and relate to American Depositary Shares representing ordinary shares of Quoin Pharmaceuticals.

What does each Quoin Pharmaceuticals (QNRX) ADS represent in ordinary shares for this option grant?

Each American Depositary Share in this option grant represents thirty-five ordinary shares of Quoin Pharmaceuticals. This means exercising one ADS option effectively corresponds to an economic interest tied to thirty-five of the company’s underlying ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leong Natalie Ee Mun

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		12,211(1)		(2)	02/04/2036	ADS	12,211(1)	$0	12,211(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Natalie Leong	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.